APKIRO Trademark Information

Trademark by AbbVie Inc.

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines

Classification Information

Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.

Primary Class: Class Details:
Class (005)
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
First Use Anywhere:: Not provided
First Use In Commerce: Not provided
General Information
Word mark: APKIRO
Status/Status Date:
ABANDONED - NO STATEMENT OF USE FILED
9/28/2020
Serial Number: 87362840
Filing Date: 3/8/2017
Registration Number: NOT AVAILABLE
Registration Date: NOT AVAILABLE
Goods and Services: Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines
Mark Description: NOT AVAILABLE
Type Of Mark: TradeMark
Published For Opposition Date: 6/27/2017
Last Applicant/Owner:
AbbVie Inc.
********
********
***** ****
Mark Drawing Code: Standard Character Mark
Design Search:
(NO DATA)
Register Type: Principal
Disclaimer: (NOT AVAILABLE)
Correspondent:
********
********
***** ****
Current Status:
ABANDONED - NO STATEMENT OF USE FILED
9/28/2020
Correspondent Search:
CHERYL A. WITHYCOMBE is a correspondent of APKIRO trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on